The study enrolled 952 women aged 18 to 65 years, recruited randomly across four socioeconomic regions of Kerman in 2024. This stratified sampling approach was designed to capture women from different social and economic circumstances rather than relying on a single clinic or neighborhood, which strengthens the representativeness of the findings for the wider urban population. Each participant completed a validated Persian-language version of the Beck Depression Inventory-II, a widely used self-report screening instrument, and a cut-off score above 14 was used to identify women with elevated depressive symptoms. In addition to the psychological assessment, the researchers measured serum levels of four key hormones: progesterone, prolactin, estradiol, and testosterone. Demographic variables including age and body mass index were also recorded, allowing the team to disentangle hormonal effects from other well-known contributors to mood.

The headline result is the sheer scale of the burden. The overall prevalence of elevated depressive symptoms was 40 percent across the sample. When the researchers split the cohort by menopausal status, the figures were remarkably similar: 39 percent of premenopausal women and 41 percent of postmenopausal women screened positive. That narrow gap between the two groups is itself informative. It suggests that the transition through menopause, often assumed to be a period of heightened psychological vulnerability, does not dramatically change the prevalence of depressive symptoms in this population, even though the hormonal milieu shifts profoundly. Postmenopausal women were only slightly more likely to report elevated symptoms than their premenopausal counterparts.

The hormonal findings are where the study becomes technically compelling. In adjusted multivariable logistic regression models, stratified by menopausal status, lower estradiol levels were independently associated with greater odds of depressive symptoms in both groups. Among premenopausal women, the adjusted odds ratio was 0.63, with a 95 percent confidence interval of 0.18 to 0.92 and a p-value of 0.038. Among postmenopausal women, the adjusted odds ratio was 0.61, with a 95 percent confidence interval of 0.23 to 0.88 and a p-value of 0.034. Because these are odds ratios for the hormone variable expressed in a direction where values below one indicate a protective association, the results mean that women with higher estradiol had lower odds of screening positive for depression, and the relationship held after accounting for age, body mass index, and other covariates.

Estradiol is the most potent form of estrogen circulating in the human body, and its influence on the brain extends far beyond the reproductive system. The hormone modulates neurotransmitter systems, including serotonin and dopamine pathways, that are central to mood regulation. It also influences neuroplasticity, cerebral blood flow, and the stress response axis. A long-standing hypothesis in reproductive neuroscience holds that declines or fluctuations in estradiol, whether across the menstrual cycle, after childbirth, or during the menopausal transition, can destabilize mood in susceptible individuals. The new findings align with that framework: in both reproductive stages, women with elevated depressive symptoms had significantly lower estradiol levels than those without, even though the absolute hormone concentrations differ enormously between premenopausal and postmenopausal women.

Equally notable is what did not predict depression. After adjustment, there were no significant associations between progesterone, prolactin, or testosterone and elevated depressive symptoms in either group. Progesterone metabolites interact with inhibitory GABA receptors in the brain and have been implicated in premenstrual mood disorders, while prolactin and testosterone have each been linked to mood in previous research with mixed results. The fact that only estradiol emerged as a significant independent predictor, consistently across both menopausal strata, sharpens the focus on estrogen signaling as the hormonal thread most tightly woven into depressive symptomatology in this cohort. It also underscores the value of measuring multiple hormones simultaneously rather than studying them in isolation, since a single-hormone analysis could easily have produced a misleading picture.

Beyond the hormonal story, the study identified demographic risk factors that echo patterns seen globally. Older age and higher body mass index were independently associated with elevated depressive symptoms in both premenopausal and postmenopausal women. The link between adiposity and depression is well documented in the international literature and is thought to involve chronic low-grade inflammation, insulin resistance, and social and psychological factors related to body image and health status. The age association is consistent with the cumulative burden of life stressors and chronic disease, although cross-sectional data cannot determine whether aging itself, or the conditions that accompany it, drives the relationship. Marital status added a further layer of nuance: divorced or widowed marital status was an additional significant predictor of elevated depressive symptoms in premenopausal women, with an adjusted odds ratio of 1.36, a 95 percent confidence interval of 1.17 to 1.59, and a p-value of 0.043. This association was not reported as significant in the postmenopausal group.

The methodological choices of the study deserve scrutiny. The Beck Depression Inventory-II is a screening tool, not a diagnostic instrument, so the 40 percent figure reflects the prevalence of elevated depressive symptoms rather than clinically confirmed major depressive disorder. Self-report measures can be influenced by somatic symptoms, cultural expression of distress, and response bias, although the Persian-language version used has been validated for Iranian populations. The cross-sectional design is the study’s principal limitation: it captures a single moment in time and cannot establish whether low estradiol causes depression, whether depression alters hormone levels, or whether both are shaped by a common underlying factor. Longitudinal designs, in which hormone trajectories are tracked alongside mood over months or years, would be needed to establish temporal direction. The authors also note that the study was not registered in a clinical trial registry, which is not mandatory for observational cross-sectional designs under current Iranian research regulations, and that the work received no external funding.

Nevertheless, the consistency of the estradiol signal across two very different hormonal contexts is what makes the study worth attention. Premenopausal women experience cyclical estradiol fluctuations at concentrations many times higher than those seen after menopause, yet in both groups the same directional relationship with depressive symptoms appeared after adjustment. This suggests that estradiol’s relevance to mood may operate relative to a woman’s own hormonal baseline rather than at any absolute threshold. For clinicians, the findings hint that reproductive hormonal status could be a meaningful consideration when assessing depression risk in women, alongside established factors such as age, body weight, and social circumstances. For researchers, they set the stage for intervention studies and mechanistic work exploring whether maintaining estradiol within physiological ranges can buffer mood, and for longitudinal cohorts that can finally separate cause from correlation in the intricate dialogue between the ovaries and the brain.

Subject of Research: Prevalence of depression in Iranian premenopausal and postmenopausal women and its association with sex hormone levels

Article Title: Prevalence of depression in Iranian premenopausal and postmenopausal women and its association with sex hormone levels

Article References: Dehesh, T., Mosleh-Shirazi, M. A., & Dehesh, P. (2026). Prevalence of depression in Iranian premenopausal and postmenopausal women and its association with sex hormone levels. BMC Psychology. https://doi.org/10.1186/s40359-026-05692-y

Image Credits: AI Generated

DOI: 10.1186/s40359-026-05692-y

Keywords: Prevalence, depression, Iranian, premenopausal, postmenopausal, women, association, hormone, levels, scientific research

The patient’s story began in September 2019, when she first noticed a small, mobile mass in her left breast measuring roughly 2 by 1 by 1 centimeters. The lump caused no tenderness, no skin changes, and no nipple discharge, so she initially ignored it. Two months later, at another hospital, mammography and breast color Doppler ultrasound both classified the lesion as Breast Imaging Reporting and Data System category III—a designation implying a probably benign finding with less than a 2 percent risk of malignancy—and recommended routine follow-up. Over the following three months, however, the mass grew dramatically, reaching approximately 4 by 3 by 2 centimeters and occasionally becoming painful. That rapid enlargement prompted her admission to the reporting hospital in March 2020, where physical examination found a smooth, moderately firm, mobile mass without skin ulceration, nipple retraction, or enlarged lymph nodes in the armpits.

The imaging workup revealed a striking contradiction. Mammography at the outside hospital had graded the lesion BI-RADS 3, but repeat ultrasound at the new institution upgraded it to BI-RADS 4A, indicating a small but real suspicion of malignancy of roughly 2 to 10 percent. The ultrasound showed a solid, irregular, lobulated mass at the 11 o’clock position of the left breast, containing strip-like blood flow signals with low-resistance arterial waveforms—a vascular pattern that would later prove telling. Chest computed tomography confirmed a mound-shaped mass in the upper inner quadrant with an unclear boundary on plain scan. Meanwhile, laboratory results were entirely unremarkable: blood counts, liver and kidney function, and coagulation were normal, and the tumor markers CEA, CA 15-3, CA 125, and CA 19-9 all sat comfortably within reference ranges. The team noted that breast angiosarcomas frequently produce negative results on routine malignant tumor markers, rendering these tests of extremely low diagnostic value in such cases.

Reconciling the discordant imaging grades against current standards proved decisive in shaping the diagnostic pathway. According to the fifth edition of the American College of Radiology BI-RADS criteria, the 2024 National Comprehensive Cancer Network breast guidelines, and the 2021 Chinese Society of Breast Surgery fibroadenoma guideline, the combined clinical and imaging picture did not meet formal indications for contrast-enhanced breast MRI, bone scintigraphy, or percutaneous core needle biopsy. Those tools are reserved for high-risk patients, radiologically indeterminate lesions with definite malignant suspicion, or preoperative staging of confirmed cancers—not for discordant low-grade BI-RADS 4A lesions accompanied by benign mammographic findings. The clinicians therefore concluded the lesion was highly suggestive of a benign fibroadenoma and recommended elective surgical resection, a decision that conformed to guidelines but, as they later acknowledged, failed to account specifically for the lesion’s rapid growth.

Surgery took place on March 11, 2020, under general anesthesia, and it was here that the case pivoted. Intraoperative frozen section pathology suggested a spindle cell tumor tending toward a vascular origin, with definitive classification awaiting immunohistochemistry. Because the team had rarely encountered such lesions, and because committing to a radical operation on an uncertain diagnosis carried obvious risks, they consulted the patient’s family and made the unusual decision to temporarily suspend the surgery. Final pathology returned on March 17: the excised nodule, about 3.5 by 2.5 by 1.8 centimeters, was packed with anastomosing slit-like vascular channels infiltrating breast lobules and fat, lined by a single layer of endothelial cells showing mild nuclear atypia and occasional mitoses. Immunohistochemistry showed strong positivity for the endothelial markers CD34, CD31, and FLT-1, along with vimentin and smooth muscle actin, while epithelial markers EMA and broad-spectrum cytokeratins were negative. The Ki-67 proliferation index was 25 percent. The diagnosis was low-grade angiosarcoma.

To be certain, the slides were sent for outside consultation at a higher-level hospital, which returned on March 20 with a confirmatory and slightly more concerning picture: part of the tumor showed the mild, well-formed vascular pattern, but other areas were solid, densely cellular, and pleomorphic with mitotic figures, extensive hemorrhage, and necrosis. The consultants recommended optional molecular testing for c-Myc, KDR, and VEGFR2—markers mainly useful for distinguishing primary from radiation-associated secondary angiosarcoma—though the team ultimately judged these unnecessary given the clear histopathological diagnosis. After a hospital-wide multidisciplinary team discussion, the patient underwent completion resection of the remaining left breast tissue plus sentinel lymph node biopsy on March 23. Frozen section confirmed an R0 resection with clear microscopic margins and no sentinel node metastasis, and final pathology found no residual cancer in the surrounding breast, nipple, skin, or basal margin, with zero of three sentinel nodes involved.

The staging and treatment decisions reflected the peculiar biology of this tumor. Under the eighth edition of the AJCC staging system, the disease was classified as stage I (T1N0M0). Unlike conventional breast carcinoma, which spreads chiefly through lymphatic channels, primary breast angiosarcoma metastasizes predominantly through the bloodstream, seeding the liver, lungs, bone, and brain early, while regional lymph node involvement is extremely rare. Routine axillary lymph node dissection is therefore not recommended, and the team performed only a sentinel node biopsy for accurate staging, sparing the patient unnecessary surgical trauma. Beginning April 3, 2020, she received eight cycles of adjuvant chemotherapy—four of doxorubicin plus cyclophosphamide followed by four of paclitaxel—completed without significant adverse reactions by the end of July 2020.

The prognosis data assembled in the report underscore why vigilance matters. Secondary angiosarcoma of the breast, which typically arises after radiotherapy for breast cancer or in the setting of chronic lymphedema known as Stewart-Treves syndrome, carries a five-year overall survival of roughly 38 percent with a recurrence-free survival of about 43 months. Primary breast angiosarcoma fares somewhat better, with a five-year overall survival near 49 percent and recurrence-free survival of about 44 months, with outcomes tied to stage, histological grade, and tumor size. Diagnosis remains the hardest part: mammography yields false negatives in roughly a third of patients because of dense glandular tissue, ultrasound lacks specificity despite showing heterogeneous masses and increased blood flow, and MRI—considered the most useful non-invasive modality—reveals heterogeneous signals and avid contrast enhancement reflecting the tumor’s rich vascularity. Core needle biopsy, the usual route to preoperative diagnosis, frequently returns false negatives because of bleeding risk and marked tumor heterogeneity, meaning most cases are only confirmed after surgery.

Emerging evidence is beginning to reshape treatment thinking for this orphan disease. A meta-analysis by Skarentzos and colleagues found that adjuvant chemotherapy significantly improved survival in primary breast angiosarcoma, with a hazard ratio of 0.11, while radiotherapy showed no survival benefit. Anthracycline-, ifosfamide-, and paclitaxel-containing regimens are considered the most effective, though the disease’s rarity means evidence rests on small series and case reports rather than large trials. Genomic research is opening new doors: the Angiosarcoma Project, a patient-partnered genomic study, has suggested that inhibitors of the phosphatidylinositol-3-kinase catalytic alpha subunit could become targeted therapeutic options, and next-generation sequencing may eventually identify actionable alterations in tumors like this one.

Follow-up tells the story’s encouraging end. The patient was re-examined at one, three, and six months after surgery, then roughly every six months, with breast ultrasound, chest CT, abdominal and urinary tract ultrasound, blood counts, and tumor markers. As of November 5, 2025—more than five years after her diagnosis—she showed no sign of local recurrence or distant metastasis. The authors argue their case carries three broader lessons: that a rapidly growing, benign-appearing breast mass in a postmenopausal woman deserves heightened suspicion even when guidelines do not mandate advanced imaging; that suspending surgery when frozen section reveals something unexpected can preserve diagnostic accuracy and prevent undertreatment; and that multidisciplinary collaboration, staged surgery, and guideline-conformant individualized therapy can deliver excellent long-term outcomes even in a cancer this rare and this easy to miss.

Subject of Research: Primary breast angiosarcoma diagnosis and treatment in a postmenopausal woman

Article Title: Primary Mammary Angiosarcoma in a Postmenopausal Woman: A Case Report

Article References: Liu, T., Xu, Y., Wang, Q., Yu, S., Lin, H., Ye, Z., Zheng, Z., Yang, C., & Hong, T. (2026). Primary Mammary Angiosarcoma in a Postmenopausal Woman: A Case Report. Cancer Reports, 9(9), Article e70653. https://doi.org/10.1002/cnr2.70653

Image Credits: AI Generated

DOI: 10.1002/cnr2.70653

Keywords: breast angiosarcoma, primary breast angiosarcoma, postmenopausal, BI-RADS, fibroadenoma, frozen section pathology, immunohistochemistry, CD31, sentinel lymph node biopsy, adjuvant chemotherapy, R0 resection, rare cancer